Stock Market Reviews

NRXP (NRx Pharmaceuticals, Inc.) News

Get the latest news, insights, and market updates on NRXP (NRx Pharmaceuticals, Inc.). Explore the news page 4 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Re-Files Abbreviated New Drug Application (ANDA) for KETAFREE™, Preservative-Free IV Ketamine
  KETAFREE™ to provide innovative, preservative-free IV ketamine formulation, eliminating toxic preservatives, in keeping with current HHS priorities to eliminate toxic preservatives from foods and drugsFiling is based on FDA interaction and approval of Suitability Petition for NRx’s proposed strength of preservative-free ketamineThis presentation of ketamine represents a reshoring of a strategically important drug to the US, in keeping with the Presidential Executive Order signed on May 5, 2025.
  Sep 29, 2025 - $NRXP
• New to The Street's Prestigious Client NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx's Proposed Strength of Preservative-Free Ketamine
  Suitability Petition is required for shift from multidose packaging of ketamine to single-patient dose preservative free ketamine Granting of Suitability Petition enables re-filing of Abbreviated New Drug Application (ANDA) for NRx's patent-pending ...
  Sep 24, 2025 - $NRXP
• NRx Pharmaceuticals (NRXP) Receives FDA Approval of Suitability Petition for Preservative-Free Ketamine Product
  LOS ANGELES, CA - September 24, 2025 (NEWMEDIAWIRE) - NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration has granted its Suitability Petition for KETAFREE(TM), a planne...
  Sep 24, 2025 - $NRXP
• NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx’s Proposed Strength of Preservative-Free Ketamine
  Suitability Petition is required for shift from multidose packaging of ketamine to single-patient dose preservative free ketamineGranting of Suitability Petition enables re-filing of Abbreviated New Drug Application (ANDA) for NRx’s patent-pending preservative-free ketamine product WILMINGTON, Del., Sept. 24, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP), a clinical-stage biopharmaceutical company, announced that it was notified yesterday by the United States Food and Drug Adm
  Sep 24, 2025 - $NRXP
• NRx Pharmaceuticals (NRXP) Subsidiary HOPE Therapeutics Closes Acquisition of Dura Medical
  LOS ANGELES, CA - September 9, 2025 (NEWMEDIAWIRE) - NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced that its wholly owned subsidiary HOPE Therapeutics Inc. has closed the acquisition of Dura Medical, a reven...
  Sep 9, 2025 - $NRXP
• HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Complete the Acquisition of Dura Medical; Initial Acquisition in Network of Interventional Psychiatry Clinics
  Dura Medical, together with pending acquisitions of Neurospa TMS and Cohen & Associates, to provide contiguous coverage at more than 8 locations along Florida’s West Coast, with planned coverage throughout the Florida PeninsulaDura delivers a full range of precision psychiatry services for severe depression and PTSD, including Ketamine Therapy and Transcranial Magnetic Stimulation (TMS), to Veterans and civilian patients Stephen Durand, CRNA, a US Army Veteran and founder of Dura will serve as D
  Sep 8, 2025 - $NRXP
• NRx Pharmaceuticals presents two keynote talks at 2025 Global Passion Project
  NRx Pharmaceuticals (NRXP) presented two keynote talks to a gathering of leading family offices and family members sponsored by the Global Passion Project and Rockefeller Capital on August 28-30, 2025 in Southampton, NY. The Company’s CEO, Prof. Jonathan Javitt, MD, MPH spoke alongside Matthew Rockefeller, Bradley Hilton and Cheryl Young of Rockefeller Capital, and representatives of leading family offices to detail plans for the Fall 2025 launch of HOPE Therapeutics clinics and a prospective un
  Sep 3, 2025 - $NRXP
• NRx Pharmaceuticals (NRXP) Secures FDA Fast Track for IV Ketamine Formulation NRX-100 in Suicidal Depression
  LOS ANGELES, CA - September 3, 2025 (NEWMEDIAWIRE) - NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration ("FDA") has granted Fast Track designation to its intravenous ke...
  Sep 3, 2025 - $NRXP